Pentobarbitone (Na)

Pentobarbitone should not be used in patients with bronchopneumonia or status asthmaticus because it could increase respiratory depression. The drug should be used cautiously in patients with major depression or suicidal ideation, because the CNS-depressant effects of the drug can exacerbate the condition. Because of reduced renal or hepatic function, geriatric patients may require reduced doses. Pentobarbital should be used cautiously in patients with uncontrolled acute or chronic pain, with renal and the hepatic disease. It should be used with caution in patients who must perform hazardous tasks because depression of the CNS can produce effects of drowsiness and loss of mental alertness.Pentobarbitone, administered parenterally, should be used with caution in cases of hypotension, pulmonary disease, or cardiovascular disease because of possible adverse hemodynamic effects. IV administration can cause respiratory depression and should be administered slowly to avoid hypotension. It should not be prescribed in high doses for prolonged use because of the potential for psychological and physical dependence. It should not recommended for use during pregnancy because fetal abnormalities have been reported. Use of pentobarbitone in the third trimester can result in physical dependence in the neonate. If used during labor, neonates should be carefully observed for signs of respiratory depression. Premature babies are particularly sensitive to respiratory depression. Caution should be done in administering these drugs to patients with skin disease who may be predisposed to allergic reactions. Pentobarbitone is excreted into breast milk and can cause CNS depression in infants of breast-feeding mothers.Tolerance and physiological dependence can occur with pentobarbitone. Abrupt discontinuation of prolonged barbiturate therapy can result in withdrawal symptoms.